Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTB101 for prevention of respiratory illness in older adults
ACTRN12619000628145Phase 3Completed
- Sponsor
- Syneos Health
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Respiratory and pulmonary disorders and Airways Infection comparing RTB101 with Placebo (2 arms). Primary endpoint: Percentage of subjects with one or more symptomatic respiratory illnesses associated with one or more laboratory-confirmed pathogens through Week 16. Started May 2019; status: completed.
02
Drugs
dactolisib
03
Conditions
Respiratory and pulmonary disordersAirways Infection
Beyond the preview
Go deeper on ACTRN12619000628145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000628145.